AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TG Therapeutics CEO to participate in Cantor Global Healthcare Conference.
ByAinvest
Thursday, Aug 28, 2025 8:04 am ET1min read
TG Therapeutics announced that CEO Michael S. Weiss will participate in the Cantor Global Healthcare Conference on September 3-5, 2025. Weiss will give a fireside chat on September 3 at 10:20am ET, and a live webcast will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases.
TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company focused on developing treatments for B-cell diseases, has announced that its CEO, Michael S. Weiss, will participate in the upcoming Cantor Global Healthcare Conference. The event will take place in New York, NY, from September 3 to 5, 2025. Weiss is scheduled to give a fireside chat on September 3 at 10:20am ET, with a live webcast available on the company's website [2].Weiss will share insights into TG Therapeutics' pipeline and progress in the development of novel treatments for B-cell diseases. The company's flagship product, BRIUMVI® (ublituximab-xiiy), has received approval from various regulatory bodies for the treatment of adult patients with relapsing forms of multiple sclerosis. The company's development pipeline includes several investigational medicines, such as Ublituximab IV, TG-1701, and TG-1801 [4].
TG Therapeutics has been actively participating in the biopharmaceutical industry, with collaborations and license agreements with various partners. The company's focus on B-cell diseases highlights its commitment to addressing unmet medical needs and improving patient outcomes [4].
The Cantor Global Healthcare Conference is a significant event for the healthcare industry, bringing together leading executives, analysts, and investors to discuss the latest trends and innovations. Weiss's participation provides an opportunity for investors and industry professionals to gain insights into TG Therapeutics' strategies and future prospects [2].
References:
[1] https://www.tradingview.com/news/gurufocus:46dcfd6a7094b:0-crwv-coreweave-stock-jumps-as-cantor-sees-trillion-dollar-ai-upside/
[2] https://www.globenewswire.com/news-release/2025/08/28/3140723/8790/en/TG-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html
[4] https://finance.yahoo.com/quote/TGTX/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet